Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that it has received Laboratory Accreditation from the College of American Pathologists (CAP) for its CLIA certified reference lab.
“Cleveland Diagnostics is committed to delivering the highest quality, clinically-actionable information to clinicians and their patients,” said Arnon Chait, Ph.D., CEO of Cleveland Diagnostics. “The CAP accreditation is a testament to the standards that we uphold in our laboratory as well as in our business. This is an important milestone in our company’s mission to develop technologies to detect cancer early, when it can be treated most effectively.”
Recognized by the U.S. federal government as being equal to or more stringent than the government’s own inspection program, the CAP Laboratory Accreditation Program is widely recognized as the gold standard in clinical laboratory accreditation. The CAP accreditation process is designed to ensure the highest standard of care for all laboratory patients and includes an intense site inspection with rigorous examination of the laboratory’s records and quality control procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management.
“We are extremely proud to receive this accreditation,” said Aimee Kestranek, COO of Cleveland Diagnostics. “This provides further evidence to physicians, patients, and partners that we are committed to maintaining the highest standards in laboratory quality and accuracy.”
About Cleveland Diagnostics, Inc.
Cleveland Diagnostics, Inc., is a commercial-stage diagnostics company developing highly efficacious, lab-friendly, affordable diagnostics tests using proprietary technology to improve cancer diagnostics. Its Solvent Interaction Analysis™ (SIA) technology investigates protein biomarkers in general circulation at the structural level (as opposed to overall biomarker concentration in blood), providing better and more direct insights regarding the protein origin on the cellular level, thus improving test specificity to the underlying disease process. Its portfolio of non-invasive cancer diagnostics will be expanding from prostate cancer to breast cancer and lung cancer, infectious diseases, and certain neurological diseases, such as Alzheimer’s disease. Visit us at ClevelandDx.com and IsoPSA.com.
About the College of American Pathologists
As the world’s largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, read the CAP Annual Report at cap.org.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210505005095/en/
Contacts
Cleveland Diagnostics, Inc.
Bob Rochelle
Phone: 216 432-2700, Ext. 2119
Bob.Rochelle@ClevelandDx.com
Source: Cleveland Diagnostics, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20210505005095/en
